EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial

Yuzhou Gui, Fan Jiang, Liang Xin, Zhe Wang, Huijuan Zhu, Yanmei Liu, Qian Chen, Jingying Jia, Yun Liu

Frontiers in Pharmacology · 29.04.2026 · 17

DOI: 10.3389/fphar.2026.1784350 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.04.2026. Verfasst von Yuzhou Gui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This clinical trial aimed to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of LW402, a preferential JAK1 inhibitor, in healthy participants, so as to provide support for its further development in treating autoimmune diseases.

Methods

The study included two phases: a single ascending dose (10–400 mg) with 54 participants and a multiple ascending dose (50–150 mg, b.i.d for 6 days plus a single dose on day 7) with 36 participants. Safety, PK (from timed blood samples), and PD (JAK1/JAK2 signaling) were evaluated.

Results

No serious adverse events were reported; only mild treatment-emergent adverse events (TEAEs), such as sinus bradycardia and gastrointestinal issues, occurred. LW402 was rapidly absorbed (median t max : 0.42–1.0 hours), with slightly super-proportional exposure and minimal accumulation, and preferentially inhibited JAK1-mediated signaling.

Discussion

LW402’s favorable safety profile, predictable PK characteristics, and selective JAK1 inhibition collectively support its continued development for the treatment of autoimmune diseases. Clinical Trial Registration http://www.chinadrugtrials.org.cn , identifier CTR20201897.

Schlagwörter

Stichwörter der Autor:innen

JAK1 inhibitorLW402pharmacodynamicspharmacokineticsphase I clinical trialsafety

Autor:innen und Institutionen

  • Drug Clinical Trial Center, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, China.
  • Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.
  • Shanghai Longwood Biopharmaceuticals Co., Ltd., Shanghai, China.

Zitieren

APA

Gui, Y., Jiang, F., Xin, L., Wang, Z., Zhu, H., Liu, Y., Chen, Q., Jia, J., & Liu, Y. (2026). Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1784350

Vancouver

Gui Y, Jiang F, Xin L, Wang Z, Zhu H, Liu Y, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1784350

BibTeX
@article{Gui2026,
  author = {Gui, Yuzhou and Jiang, Fan and Xin, Liang and Wang, Zhe and Zhu, Huijuan and Liu, Yanmei and Chen, Qian and Jia, Jingying and Liu, Yun},
  title = {Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1784350}
}
Kostenlos starten →